TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

/PRNewswire/ -- TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics...

Related Keywords

United States ,South Korea ,Boston ,Massachusetts ,Seongnam ,Kyonggi Do ,American ,Tiumbio Kosdaq ,Hun Taek Kim ,Suna Cho ,Junseok Jang ,Corporate Communications Investor Relations ,Tiumbio Co Ltd ,American Society Of Clinical Oncology ,Prnewswire Tiumbio Co Ltd ,Head Of Corporate Communications Investor Relations ,Linkedin ,Clinical Oncology ,Corporate Communications ,